Norge - norsk - Statens legemiddelverk

acd pharmaceuticals (2) - benzokain - konsentrat til bad, oppløsning - 200 mg/ ml

Norge - norsk - Statens legemiddelverk

virbac s.a. - benzokain - konsentrat til behandlingsoppløsning til fisk - 200 mg/ ml

Norge - norsk - Statens legemiddelverk

orion corporation - espoo - benzokain - konsentrat til bad, oppløsning

Norge - norsk - Statens legemiddelverk

naqua ltd - trikainmesilat - pulver til behandlingsoppløsning til fisk - 1000 mg/ g

Den europeiske union - norsk - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin benzoate, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;in combination with pioglitazone (i. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;in combination with insulin (i. triple kombinasjon terapi) som et tillegg til diett og trening for å bedre glykemisk kontroll hos pasienter når insulin på en stabil dose og metformin alene ikke gir tilstrekkelig glykemisk kontroll.

Den europeiske union - norsk - EMA (European Medicines Agency)

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Den europeiske union - norsk - EMA (European Medicines Agency)

advanced accelerator applications - edotreotide - neuroendocrine tumors; radionuclide imaging - diagnostiske radiopharmaceuticals - dette legemidlet er kun til diagnostisk bruk. etter radiolabelling med gallium (68ga) klorid løsning, løsning av gallium (68ga) edotreotide fått er indikert for positron emisjon tomografi (pet) avbildningen av somatostatin reseptor overexpression hos voksne pasienter med bekreftet eller mistenkt godt differensiert gastro-enteropancreatic nevroendokrine svulster (gep-net) for lokalisering av primære svulster og deres metastaser.

Den europeiske union - norsk - EMA (European Medicines Agency)

bavarian nordic a/s - modifisert vaccinia ankara - bavarian nordic (mva-bn) virus - smallpox vaccine; monkeypox virus - andre viral vaksiner, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 og 5. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - bryst neoplasms - endokrin terapi, anti-østrogener - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. i pre - eller perimenopausal women, kombinert behandling med palbociclib bør kombineres med en luteiniserende hormon-frigjørende hormon (lhrh) agonist.

Den europeiske union - norsk - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - bryst neoplasms - antineoplastiske midler - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.